Global Tensions as a Backdrop Uncertainty, not Inflation may direct the Fed's next move. As global markets react to ripples from the Iran conflict, the Fed is expected to keep current interest rates steady. Traditional economic signals are harder to interpret in the wake of geopolitical shocks; reflexive decision making can do more harm than … Continue reading Geopolitics and Monetary Policy: Why Big Pharma Should Wait & See
Insidious CMC Risks in Regulatory Filings
As the FDA notes, many IND delays can be tied to CMC challenges. Quite often, warning signs are visible - analytical methods that are good enough but hard to scale- process steps that rely on the skills of an operator or one site- issues on stability or delivery that are shelved into future work.Such considerations … Continue reading Insidious CMC Risks in Regulatory Filings
Biotech Sector, Investor confidence, Cautious optimism
After being stagnant since 2022, the Biotech sector now shows renewed growth. Biotech ETF (XBI) has outperformed the S&P 500. So, perhaps it's time for cautious optimism for investors, acquirers, and innovators. Quiet Comeback Biotech ETF has grown 5% in the last month compared to the 0.2% growth of the S&P 500. This might not … Continue reading Biotech Sector, Investor confidence, Cautious optimism
Lilly Scoops up Adverum for $261M, with CVR and Loan
Adverum Biotechnologies (ADVM:NASDAQ) is being acquired by Eli Lilly and Company for $261M. While the acquisition proposes a transfer of $261M from Lilly to Adverum's stockholders, it is structured through a milestone payment and a bridge-loan. Payment Snapshot Upfront - $3.56/shareCVR - max $8.91/share contingent upon FDA approval and target sales of Ixo-vec.Bridge Loan - … Continue reading Lilly Scoops up Adverum for $261M, with CVR and Loan
Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
Pfizer has signed a momentous agreement with the US Federal government. Here's a snippet of what Pfizer gets and what we get (to be instituted in 2026): Quick Outline Pfizer will adhere to the most favored nation (MFN) pricing for all sales to Medicaid. So, Medicaid, usually the biggest customer to big pharma, will pay … Continue reading Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
Arnatar Tx Launches with $52M in Series A funding
Arnatar Therapeutics has launched with $52M in VC funding to create a dual-modality RNA platform. Its first target is Alagille syndrome (ALGS). Arnatar Details Innovative Nucleic Acid drug development Chinese origin, founded in 2022 using $14.45M from Apricot Capital. Operated in Stealth mode until Series A in 2025 HQ in San Diego, CASource: CapitalIQ.com Series … Continue reading Arnatar Tx Launches with $52M in Series A funding
Why Biotech Deals Keep Coming with CVRs
When Concentra bought iTeos earlier this year, the headline number—$10.047 per share—looked underwhelming. In fact, it was at a slight discount to what the stock was trading at the day before. But buried in the fine print was something intriguing: a non‑transferable contingent value right (CVR) promising iTeos shareholders maybe more later if the company … Continue reading Why Biotech Deals Keep Coming with CVRs
FDA approvals in just 60 days?
The FDA has launched the Commissioner's National Priority Voucher (CNPV) program, offering 1-2 month reviews, so drug developers can get faster market access for products that align with national priorities. Some examples could be:1. Strengthening US employment in development & manufacturing2. Ensuring that clinical trials have robust US patient population3. Affordability of drug products by … Continue reading FDA approvals in just 60 days?
Novartis acquires Regulus Therapeutics for $1.7B
Novartis (NYS) completed on 25 June the $1.7B acquisition of Regulus Therapeutics (RGLS), a clinical-stage biotech company that will strengthen Novartis' renal disease pipeline. Regulus Therapeutics was formed in 2007 through a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals with microRNA as the primary focus. Novartis announced its intent to acquire Regulus for $800M … Continue reading Novartis acquires Regulus Therapeutics for $1.7B
Biotech M&A – Three Trends to notice
Most biotech M&A coverage correctly highlights where capital is flowing, which therapeutic areas are hot, and which companies are poised to shape the future of medicine. For BD, corporate strategy, or investing, such information is useful. It gives context. It sets benchmarks. And it surfaces the big moves worth watching. But that's only part of … Continue reading Biotech M&A – Three Trends to notice
BK talks Biopharm 